Dabigatran etexilate mesylate is an oral capsule medication available in a 150 mg dosage [1]. This anticoagulant, marketed under the brand name Pradaxa, is used to prevent stroke and systemic embolism in individuals with non-valvular atrial fibrillation [2]. It also treats deep vein thrombosis (DVT) and pulmonary embolism (PE) and is used for their prevention [2].
How does dabigatran etexilate mesylate work?
Dabigatran etexilate mesylate functions as a direct thrombin inhibitor [3]. Thrombin is a key enzyme in the blood clotting cascade. By inhibiting thrombin, the medication reduces the formation of blood clots [3]. The 150 mg dosage is one of the available strengths for this medication [1].
When does dabigatran etexilate mesylate patent expire?
Information regarding specific patent expiry dates for dabigatran etexilate mesylate can be found on patent tracking websites like DrugPatentWatch.com [4]. Patents are crucial for protecting the exclusivity of a drug and influencing the introduction of generic alternatives [4].
Can generic versions of dabigatran etexilate mesylate be made?
The development of generic versions of dabigatran etexilate mesylate is dependent on patent status and regulatory approvals. Once patents expire and regulatory hurdles are cleared, generic manufacturers can produce and market their versions of the drug, potentially at a lower cost [4].
What are the risks associated with dabigatran etexilate mesylate?
The primary risk associated with dabigatran etexilate mesylate is bleeding, which can be serious and potentially fatal [2]. Other side effects may include indigestion, stomach pain, and nausea [2].
How does dabigatran etexilate mesylate compare to other anticoagulants?
Dabigatran etexilate mesylate belongs to a class of direct oral anticoagulants (DOACs). It is often compared to other DOACs such as rivaroxaban (Xarelto) and apixaban (Eliquis), as well as older anticoagulants like warfarin [5]. These comparisons typically focus on efficacy, safety profiles (particularly bleeding risks), dosing convenience, and monitoring requirements [5].
What are patients asking about dabigatran etexilate mesylate?
Patient inquiries often revolve around the medication's effectiveness in preventing strokes, potential side effects, and the management of bleeding risks. Questions also frequently concern the cost of the drug, the availability of generics, and how it compares to other blood thinners [2, 5].
What clinical data supports dabigatran etexilate mesylate use?
Clinical trials have demonstrated the efficacy of dabigatran etexilate mesylate in reducing stroke and systemic embolism in patients with non-valvular atrial fibrillation. Studies have also shown its effectiveness in treating and preventing DVT and PE [2].
Who manufactures dabigatran etexilate mesylate?
Dabigatran etexilate mesylate is manufactured by Boehringer Ingelheim under the brand name Pradaxa [6].
Sources:
[1] https://www.drugs.com/dabigatran.html
[2] https://www.mayoclinic.org/drugs-supplements/dabigatran-oral-route/proper-use/drg-20071658
[3] https://www.rxlist.com/script/main/mobilearticl/index?articlekey=95971
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717517/
[6] https://www.boehringer-ingelheim.com/us/medicines/pradaxa